Marshall Wace’s Insight Molecular Diagnostics IMDX Stock Holding History

Marshall Wace’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97.9K	Buy	+16,597	New	+$81.9K	﹤0.01%	2930
2021 Q4	–	Sell	-3,161	Closed	-$225K	–	4174
2021 Q3	$225K	Sell	3,161 -3,775	-54%	-$347K	﹤0.01%	2762
2021 Q2	$796K	Sell	6,936 -10,998	-61%	-$1.07M	﹤0.01%	1922
2021 Q1	$1.86M	Buy	17,934 +17,143	+2,167%	+$1.63M	0.01%	1363
2020 Q4	$38K	Buy	+791	New	+$29K	﹤0.01%	1819
2019 Q2	–	Sell	-198	Closed	-$16K	–	1695
2019 Q1	$16K	Buy	+198	New	+$12.8K	﹤0.01%	1638

Other funds holding IMDX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

FOR

Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Marshall Wace's IMDX Position: Q2 2026 in Review

Marshall Wace opened a new position in Insight Molecular Diagnostics (IMDX) in Q2 2026: 16,597 shares worth $97.9K. The stake represents ﹤0.01% of the portfolio and ranks #2930 among its holdings. This is a return to the name: Marshall Wace previously reported a position in IMDX as recently as Q3 2021.

Marshall Wace first reported a position in IMDX in Q1 2019 and has held it in 6 quarters since. The position peaked at $1.86M in Q1 2021. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

Marshall Wace held 16,597 shares of Insight Molecular Diagnostics worth $97.9K as of Q2 2026.
Insight Molecular Diagnostics was a new Marshall Wace position in Q2 2026.
Insight Molecular Diagnostics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2930 holding.
Marshall Wace first reported a position in Insight Molecular Diagnostics in Q1 2019 and has held it in 6 quarters since.
Marshall Wace's Insight Molecular Diagnostics position peaked at $1.86M in Q1 2021.
40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.